Quorus Technology’s mission is to provide our clients with the premier stem cell cryopreservation service and to advance regenerative medicine.
Pride in our people, our practices and our potential to save lives.
Founded in 1989, Quorus Technology was the world's first private cord blood bank to separate and store stem cells in 1992. Today, the company has over 500,000 clients worldwide from 87 countries. Since inception, 100% of our clients’ specimens have been successfully viable upon thaw. View Transplant Record
. Our services include umbilical cord blood and cord tissue.
Some cord blood banks are simply marketing outlets that do not perform their own processing or storage. Quorus Technology operates its own state-of-the-art processing, testing and cryopreservation operation. We are in complete control of every step, ensuring the highest quality available today.
Quorus Technology’s laboratory operates in accordance with the guidelines set forth by Dr. Linda Kelley, Quorus Technology’s Chief Scientific Officer from 2012 - 2014. Dr. Kelley is the world’s preeminent auditor of cord blood bank laboratories and, just prior to joining Quorus Technology, served as the director of the stem cell laboratory at Harvard’s Dana-Farber Cancer Institute.
In the Quorus Technology laboratory, only qualified technologists handle specimens, and the specimens are individually processed using the industry’s gold standard method to maximize the recovery of stem cells.
Saneron CCEL Therapeutics, Inc.
Quorus Technology holds an interest in more cord blood patents than any other cord blood bank through its equity position in Saneron CCEL Therapeutics (Saneron), a University of South Florida spin-out biotechnology company. Saneron is committed to advancing research using readily available, non-controversial cord blood stem cells. Saneron’s research focus is to actively seek new cellular therapy discoveries for treatment of and intervention in devastating, life-threatening illness and conditions such as heart attack, Alzheimer’s disease, stroke, and spinal cord injury. For more information, visit Saneron’s Web site: www.saneron-ccel.com